TargetCancer Foundation is guided by the collaborative efforts of talented and committed individuals who serve on our various Boards. Learn more about them below.
C.J. is a partner at Pilgrim Strategies, LLC, a Massachusetts based public affairs firm specializing in political and media strategy for private sector clients. He develops and executes long term strategic plans for clients facing high profile governmental policy, permitting and regulatory matters in various market sectors. He serves as a political advisor to United States Congressman Bill Keating. C.J. received his B.A. in Economics and Political Science from Stonehill College.
Charles is a Co-Managing Partner of Choate Hall & Stewart, a large Boston law firm. He provides wealth management services to individuals and families, and serves as a professional trustee for accounts worth more than $500 million. He also speaks extensively throughout Massachusetts about estate planning and wealth management strategies. Charles received his B.A. from Harvard University, and his J.D. from the University of Virginia.
Sam is a litigation partner in the Boston office of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., where he spends most of his time representing clients in the life sciences industry, including biotech, pharmaceutical, medical device and diagnostic companies. Sam received his B.A. in American history from Connecticut College, and his J.D. from Northeastern University School of Law. In addition to his work with TargetCancer Foundation, Sam also serves as a trustee of Manoment Center for Conservation Sciences and Chair of the Duxbury Bay Management Committee.
Janet E. Fine, M.S.
Since the early 1980s, Janet has been at the forefront of the Victims Movement in various direct service and leadership positions locally and nationally, promoting advancements in victim rights and services, system reform and the development of innovative programs and services for victims of abuse and violence. She has served on the boards of state and national victim service organizations, was a member of the National Crisis Response Team at Ground Zero in the aftermath of 9/11, and was a founder of the Massachusetts Victim Assistance Academy. Currently at Northeastern University, she is the Project Director for the national, federally funded Vicarious Trauma Toolkit Project, addressing the needs of first responders, victim service providers, and their organizations, and is adjunct faculty at Northeastern University’s School of Criminology and Criminal Justice. She also provides training and consultation on victim rights and services and organizational and program development locally, nationally, and internationally. She received her B.S. in Human Development & Family Studies from Cornell University and her M.S. in Criminal Justice from Northeastern University.
Alicemarie is an Assurance Partner at the Boston office of PricewaterhouseCoopers LLP, serving large multinational public companies as well as private equity backed start-up companies in the technology industry. In addition to her client role, she leads the campus recruiting program for the Firm at Boston College. Alicemarie earned her BS in Accounting from Boston College. Previously, Alicemarie served on the board of directors at Historic Neighborhoods and hopeFound.
Mary Pat Lancelotta
Mary Pat Lancelotta is a seasoned healthcare market strategist with a passion for precision medicine in oncology. She provides strategic marketing advisory services to early stage companies in the life sciences industry, bringing over 15 years of business and strategy experience in Big 5 and boutique consulting firms, Fortune 500 companies and biotech start-ups. Mary Pat holds an MBA from Columbia Business School and a BS in Biochemistry from Boston College.
Since joining TargetCancer Foundation in 2010, Jim has overseen its growth from a small start-up to a nationally recognized foundation supporting comprehensive rare cancer research programs and patient support services. Prior to joining TargetCancer Foundation, Jim spent eleven years at Fidelity Investments in Boston, MA. In May 2012, Jim completed studies at the Institute for Nonprofit Management and Leadership at the Questrom School of Business at Boston University. In January 2017, Jim was named to the Board of Directors of the National Organization for Rare Disorders (NORD). Jim attended Loyola University Maryland, where he received a B.A. in Writing and Political Science.
Kristen Palma Poth
Kristen has worked in public service her entire career. She began as a Victim Witness Advocate in the Suffolk County District Attorney’s Office in Boston, where she met her husband Paul Poth, founder of TargetCancer Foundation. She worked as a project manager for youth development programs for the Massachusetts Attorney General’s Office, as well as the Public Affairs Director for the Massachusetts Office for Victim Assistance. In addition, she served as a working group leader at the United Nations Conference for the Establishment of an International Criminal Court in Rome, Italy. She received her BA from Skidmore College and a Masters in International and Public Affairs from Columbia University.
Kristen Schuler Scammon
Kristen is a founding partner of the Boston law firm Torres, Scammon & Day, LLP, a litigation boutique. Kristen’s litigation practice focuses on white collar criminal defense, corporate compliance and general business litigation for clients in a wide range of industries, including construction, security and financial services. Kristen received her B.A. in Government and Spanish from Colby College, and her J.D. from Boston College Law School. In addition to her work with TargetCancer Foundation, Kristen also serves as President of the Parent Teacher Organization at her daughter’s school in North Reading, MA.
Adam is a partner in the Boston office of the law firm Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. His practice encompasses a wide range of litigation matters, with an emphasis on securities-related issues, and includes significant federal and state court trial experience. Adam has also served as a Special Assistant District Attorney in the Middlesex County (MA) District Attorney’s Office, where he prosecuted and tried numerous criminal cases. He received his B.A. in political science from The American University, his M.A. in public administration from Framingham State College, and his J.D. from New England School of Law. In addition to TargetCancer Foundation’s Board, Adam also serves on the boards of Jewish Family Service of Metrowest, and Greater Boston Legal Services.
R. Robert Popeo
Chairman, Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo PC
R. Robert (Bob) Popeo is the Chairman of the law firm Mintz, Levin, Cohn, Ferris, Glovsky and Popeo PC. He is credited with establishing the firm’s Litigation Practice as well as its nationally recognized White Collar Criminal Defense Practice, and is a longtime leader of the Boston legal community. Known as a brilliant strategist and “a force of nature at the Bar,” Bob has tried some of the most highly publicized white collar criminal cases in the country. He has played a key role in reforming the Massachusetts court system and has been an integral part of the fabric of Boston’s business and civic community for over 40 years.
Bob’s reputation for excellence and success does not stop with the practice of law. He is known and respected for his commitment to pro bono work, and has established a pro bono practice at his firm that is a model nationwide. From its first days, Bob supported TargetCancer Foundation’s mission. That support continues today, ensuring TargetCancer Foundation’s growth and success.
James Bradner, MD
Dr. Bradner is President of the Novartis Institutes for Biomedical Research. Prior to joining Novartis, Dr. Bradner was an Associate Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School in Boston, MA. His clinical practice centered around the treatment of hematologic malignancies, specifically using allogeneic stem cell transplantation. Additionally, he led a research laboratory focused on the discovery, optimization and clinical translation of new targeted cancer therapeutics. Dr. Bradner received an A.B. from Harvard University, a M.D. from the University of Chicago-Pritzker School of Medicine and a M.M.S. from Harvard Medical School. He completed postdoctoral research training with Prof. Stuart Schreiber in the Department of Chemistry and Chemical Biology at Harvard University and the Broad Institute of Harvard and MIT. Learn more about Jay by watching his Ted talk, or by reading about him in Nature.
Todd Foley is a managing director with MPM Capital, one of the world’s largest life-science focused venture capital firms. Prior to joining MPM, Mr. Foley worked in business development at Genentech and in management consulting with Arthur D. Little. Mr. Foley currently serves as a member of the board of directors of Chiasma (NASDAQ: CHMA), ClinicalInk, Iconic Therapeutics, Motus Therapeutics, Rhythm Pharmaceuticals, Selexys Pharmaceuticals, Semma Therapeutics, and Tetherex. He holds a B.S. in chemistry from MIT and an MBA from Harvard Business School.
John Iafrate, MD, PhD
Dr. Iafrate is the director of the Center for Integrated Diagnostics, a clinical laboratory for molecular diagnostics at Massachusetts General Hospital. He oversees the Translational Research Laboratory (TRL), a shared effort of the Pathology Department and Mass General Cancer Center. The TRL provides rapid personalized genomic testing to help inform cancer treatment decisions for patients. Dr. Iafrate received his MD, PhD degrees from the State University of New York at Stony Brook in 2000, and was trained in anatomic and molecular genetic pathology at Brigham and Women’s Hospital. He joined the Massachusetts General Hospital staff in 2005. His post-doctoral work involved the discovery and description of a novel source of human genetic diversity, termed “copy number variation” (CNV). He established a cancer diagnostics lab focusing on genetic fingerprints that help guide novel, targeted therapies. His laboratory launched SNaPshot several years ago, an assay that tests over 100 of the most common mutations in tumors. His research is focused on lung and brain tumors, and he has been closely involved in the clinical development of crizotinib and companion diagnostics in ALK-positive lung cancers.
Deborah Morosini, MD
Dr. Morosini is the Vice President of Clinical Affairs and Patient Engagement at Loxo Oncology. Prior to joining Loxo, Dr. Morosini was Vice President of Clinical Development at Foundation Medicine. Dr. Morosini has a particular passion for the genomics of adolescent and young adult (AYA) cancer. Inspired by her late sister and brother-in-law, Christopher and Dana Reeve, she has devoted her energies to raising awareness and research dollars for cancer research and early detection. She has been a featured spokesperson for numerous non-profit fundraising and government events in oncology and has provided expert commentary for national television and radio broadcasts, including NBC, ABC, CNN and FOX News. Dr. Morosini received her MD from Boston University School of Medicine and completed a pathology residency at Boston Medical Center, where she was chief resident. She served on the NCI – DCLG board, and currently serves on the Board of Directors for the Lung Cancer Alliance, the National Comprehensive Cancer Network Foundation, the NPAF Scientific Advisory Board and the Cancer Support Community in Central New Jersey.
Jeffrey Settleman, PhD
Dr. Settleman’s research is focused on cellular signaling pathways in human cancer. His current research is primarily related to molecularly targeted cancer therapeutics, personalized cancer medicine, and mechanisms of drug resistance. He received a Ph.D. degree in Genetics from Yale University in 1989, and from 1989-1992 was a postdoctoral fellow at the Whitehead Institute for Biomedical Research at M.I.T. in Dr. Robert Weinberg’s laboratory. He joined the Harvard School of Medicine faculty in 1992, and was named the Laurel Schwartz Professor of Oncology at Harvard Medical School in 2008. He was also the Director of the Center for Molecular Therapeutics and the Scientific Director of the Massachusetts General Hospital Cancer Center. In 2010, Dr. Settleman joined Genentech, as the Senior Director of Discovery Oncology, and in 2015, moved to Calico Life Sciences as the Head of Oncology Research.
Lori Stetz, MD
As Senior Medical Director for Aetna International, Dr. Stetz provides guidance, support, and medical leadership for all care management activities around the globe. She drives medical policy, and actively participates in strategic planning and program and product development in concurrence with changing markets and technologies. Dr. Stetz also manages Aetna International’s emergency evacuation program, helping to ensure appropriate healthcare delivery for our members around the globe. Prior to joining Aetna in 2009, Dr. Stetz practiced primary and urgent care medicine and public health in the U.S. and a number of international settings, including Kosovo, Thailand, and Nepal. She is certified by the American Board of Family Medicine and has special certification in Travel Medicine. Dr. Stetz graduated from Haverford College, and holds an M.P.H. from Boston University and an M.D. from SUNY Downstate.
Jim has over 20 years of experience in the music business as a record company executive, artist manager, and musician. He began his career at Rounder Records, one of the most respected independent labels in the country, where he rose to become the company’s Vice-President and General Manager while working with artists such as Robert Plant, Gregg Allman, Alison Krauss, John Mellencamp, Rush, The Jayhawks, Steve Martin, and They Might Be Giants. He currently manages the Grammy-nominated string band Della Mae and teaches music business for the Berklee College of Music. He is also a singer, songwriter, and guitarist, who has been performing for over 25 years, most recently with the Boston-based country band, Georgia Overdrive.
Ed is a record producer and musician who manages both the recording studio and record label at Q Division – a world-class recording facility and independent record label in Somerville, MA. In 2008, he won a Boston Music Award for “Best Producer” for his work with international neo-soul artist Eli “Paperboy” Reed. He has played bass with local favorites The Gravel Pit for the last 20 years, and most recently with the retro-60’s Girl Group inspired Jenny Dee&The Deelinquents, who opened up the legendary J. Geils Band/Aerosmith show at Fenway Park. He has recorded and toured with Juliana Hatfield and Graham Parker. In addition to his work with TargetCancer Foundation, Ed has been involved with Baseball Hall of Fame Sportswriter Peter Gammons and Boston Red Sox GM Theo Epstein’s annual “Hot Stove, Cool Music” charity fundraiser as both an organizer and a musician for the last 10 years.
The TargetCancer Foundation Advocacy Council is dedicated to empowering volunteers through increased support of TargetCancer Foundation’s mission, including rare cancer awareness, rare cancer research, and patient support. The Council is Co-Chaired by Leslie Condon and Lisbeth Garassino, who both became involved with TargetCancer Foundation as volunteers after losing siblings to cholangiocarcinoma.
What kind of activities have Advocacy Council members participated in on behalf of TargetCancer Foundation?
- Helped at an event or planned one of their own
- Traveled to a scientific conference to represent TCF
- Wrote for the TCF Blog
- Became a patient liaison
- Trained to become a legislative advocate
- Served on the Gala planning committee